MOTS-c (20 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

MOTS-c (mitochondrial open reading frame of the twelve-S rRNA type-c) is a 16-amino-acid mitochondrial-derived peptide studied for its role in metabolic regulation and cellular stress responses. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound has been handled and dosed in published research models, not a recommendation for use in humans or animals.

For a 20 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of roughly 6.67 mg/mL (about 6,670 mcg/mL). At that fill, each unit drawn on a U-100 insulin syringe equals 0.01 mL and delivers approximately 66.7 mcg, so a 200 mcg step works out to about 3 units. The larger diluent volume keeps the small microgram doses easy to measure on a standard syringe scale.

Standard (Gradual) Titration Schedule

The gradual schedule reflects the slow, stepwise escalation used to model tolerability, with each daily level held for roughly two weeks before advancing. Dosing in the published model is once daily by subcutaneous administration.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (6.67 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Dosing Frequency & Cadence

Unlike the once-weekly incretin agonists, the MOTS-c research model uses a once-daily subcutaneous cadence, which is why the per-dose volumes stay small even at the top of the band. The published source does not describe a separate aggressive or high-ceiling arm — escalation simply caps at the 1.0 mg daily step after the gradual ramp.

Supplies Needed

• MOTS-c vials (20 mg): ~2 vials for an 8-week run; ~3 vials for 12 weeks; ~5 vials for a 16-week run at the daily cadence.
• Insulin syringes (U-100, 1 mL): ~56 for 8 weeks, ~84 for 12 weeks, ~112 for 16 weeks — one fresh syringe per daily draw.
• Bacteriostatic water (10 mL): one bottle covers an 8–12 week run; two bottles for a 16-week, 5-vial schedule.
• Alcohol swabs: ~112 for 8 weeks (two 100-count boxes), scaling to ~224 (three boxes) for 16 weeks.

Protocol Overview

• Research goal: model metabolic homeostasis via AMPK activation and mitochondrial retrograde signalling.
• Schedule: once-daily subcutaneous administration in the published model.
• Dose band: 200–1000 mcg daily, titrated over roughly ten weeks.
• Fill: 20 mg lyophilized, reconstituted to 6.67 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 200 mcg step and hold each level for about two weeks before escalating.
• Keep administration on a fixed daily cadence at roughly the same time for steady exposure modelling.
• Escalate only after tolerability is established at the prior step.
• Because doses are small, double-check the unit count on the syringe before each draw — a one-unit error is proportionally large at the 200 mcg step.

Storage Instructions

Keep sealed lyophilized vials at −20 °C or below, protected from light and dry (add desiccant if available), where stability extends for many months. Once reconstituted, refrigerate at 2–8 °C away from light and use within about seven days for best potency; one source notes roughly 25% activity loss after 24 hours at 4 °C, so prompt use matters. Avoid repeated freeze-thaw cycles, and if freezing at −20 °C, prepare single-use aliquots in advance.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate sampling/handling technique to keep the stopper intact.
• Measure the small microgram volumes carefully — the daily steps sit between 3 and 15 units.
• Document each draw — date, volume, remaining material — for reproducibility.

How MOTS-c Works

MOTS-c is a mitochondrial-derived peptide that activates AMP-activated protein kinase (AMPK), in part by inhibiting the folate cycle and allowing AICAR to accumulate. This shifts cells toward an energy-efficient state: greater glucose uptake, fatty-acid oxidation and mitochondrial respiration, with reduced fat storage and gluconeogenesis. Under cellular stress, the peptide translocates to the nucleus and upregulates antioxidant and stress-response genes through retrograde mitochondrial-to-nuclear signalling, with additional modulation of mTOR and inflammatory pathways. At the cellular level its effects have been likened to those of exercise and metformin.

Reported Benefits & Side Effects

Benefits observed in preclinical models

• Improved insulin sensitivity and prevention of diet-induced insulin resistance in animal studies.
• Reduced visceral fat accumulation and resistance to diet-induced obesity via increased energy expenditure.
• Mitigation of metabolic decline in ovariectomized (post-menopausal) models.
• Enhanced exercise capacity — aged mice ran roughly twice as long on a treadmill in one study.
• Reduced liver fat, supportive effects on cardiac function and bone (favouring osteoblast over osteoclast activity), and modulation of immune aging.

Side effects reported

• No adverse effects were reported across the preclinical studies; human tolerability remains unknown.
• A modified analog (CB4211) was reasonably tolerated in a Phase 1 trial, but MOTS-c itself lacks completed human safety data.
• Because no human trials are finished, all safety inferences are preliminary and laboratory-bound.

Supporting Lifestyle Factors (Research Context)

• Exercise is a recurring co-variable in the literature — MOTS-c is itself partly an exercise-responsive peptide, so physical activity is often the comparator in study designs.
• Caloric and dietary composition controls, given the compound's role in glucose and fat metabolism.
• Standard trial controls for sleep, hydration and stress management.

Injection Technique (Reference Only)

• Clean the vial stopper and the site with alcohol swabs and let both dry completely.
• Pinch a skinfold and insert subcutaneously at roughly 90° (45° if very lean); aspiration is not required for subcutaneous work.
• Inject slowly and steadily over a few seconds, then withdraw at the same angle and apply gentle pressure without rubbing.
• Rotate sites systematically — abdomen (at least two inches from the navel), outer thighs and the back of the upper arms — and dispose of sharps in an approved container.

References

Related Protocols